Clinical Trials Logo

Metastatic Solid Tumor clinical trials

View clinical trials related to Metastatic Solid Tumor.

Filter by:

NCT ID: NCT05983523 Not yet recruiting - Clinical trials for Advanced Solid Tumor

A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced or Metastatic Solid Tumors

Start date: December 28, 2023
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is To establish the safety profile and determine the dose-limited toxicity (DLT) of PEP07 monotherapy in patients with advanced or metastatic solid tumors. To determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of PEP07 monotherapy. Participants will receive PEP07 administered orally once daily (QD) for 2 consecutive days and 5 days off, every week for 4 weeks until disease progression, intolerable toxicity, confirmed pregnancy, death, consent withdrawal, or other anti-cancer treatment is required, or the Sponsor ends the study, whichever occurs first.

NCT ID: NCT05935098 Recruiting - Solid Tumor Clinical Trials

A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors

Start date: August 21, 2023
Phase: Phase 1
Study type: Interventional

This study aims to test the safety, tolerability, and preliminary anti-tumor activity of BGB-A3055, either alone or in combination with Tislelizumab in participants with advanced or metastatic solid tumors.

NCT ID: NCT05919537 Recruiting - Clinical trials for Non-Small Cell Lung Cancer

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

Start date: September 6, 2023
Phase: Phase 1
Study type: Interventional

This is a phase 1b multi-center, open-label study of HMBD-001 with or without chemotherapy in participants with advanced solid tumors harboring NRG1 gene fusions or selected HER3 mutations.

NCT ID: NCT05898399 Recruiting - Clinical trials for Advanced Solid Tumor

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients

Start date: June 30, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This interventional study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ART6043 as monotherapy or in combination with Olaparib or Talazoparib.

NCT ID: NCT05875168 Recruiting - Clinical trials for Advanced Solid Tumor

First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

Start date: August 18, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the safety, tolerability, and efficacy of DS-3939a in participants with advanced solid tumors.

NCT ID: NCT05872867 Recruiting - Colorectal Cancer Clinical Trials

Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90)

Start date: March 14, 2024
Phase: Phase 1
Study type: Interventional

The purpose of the present study is to determine the safety, tolerability, and efficacy of WM-A1-3389 in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancer (NSCLC).

NCT ID: NCT05867121 Recruiting - Clinical trials for Non-small Cell Lung Cancer

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Start date: October 2, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of RO7496353 when administered in combination with a checkpoint inhibitor (CPI) with or without standard-of-care (SOC) chemotherapy in participants with locally advanced or metastatic solid tumors such as non-small cell lung cancer (NSCLC), gastric cancer (GC) and pancreatic ductal adenocarcinoma (PDAC). The study will be conducted in 2 stages: an initial safety run-in stage and an expansion stage.

NCT ID: NCT05863052 Active, not recruiting - Melanoma Clinical Trials

Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population

Start date: January 31, 2022
Phase:
Study type: Observational

The aim of this study is to describe the outcomes in American Indian patients receiving immunotherapy in a multi-institution retrospective study at several other high-volume centers that care for this patient population and to identify any healthcare disparities that can lead to future interventional studies.

NCT ID: NCT05862324 Recruiting - Clinical trials for Metastatic Solid Tumor

TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)

TACTIC-3
Start date: August 23, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

TAC01-CLDN18.2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes Claudin 18.2. TAC directs T-cells to the targeted antigen (CLDN 18.2), and once engaged with the target, activates them via the endogenous T cell receptor. This is an open-label, multicenter Phase ½ study that aims to establish safety, maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D), pharmacokinetic profile and efficacy of TAC01-CLDN18.2.

NCT ID: NCT05856981 Recruiting - Solid Tumor, Adult Clinical Trials

Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors

Start date: April 3, 2023
Phase: Phase 1
Study type: Interventional

This first-in-human, open-label, multicenter, multi-arm dose-escalation study is designed to evaluate the safety, PK, and PD of ADU-1805, an anti- SIRPĪ± monoclonal antibody, as monotherapy and in combination with pembrolizumab (anti-PD-1 antibody).